Table 2.
The classification of HDAC inhibitors
| Compounds | Selectivity | Potency | Clinical status |
|---|---|---|---|
| Hydroxymates | |||
| SAHA (vorinostat) | pan | µM | Approved, II/III |
| PXD101 (belinostat) | pan | µM | Phase I/II |
| 4SC-201 (resminostat) | pan | µM | Phase I, II |
| PCI24781 (CRA-024781) | pan | nM | Phase I |
| LBH589 (panobinostat) | pan | nM | Phase II/III |
| LAQ824 | pan | nM | Phase I |
| Cyclic tetrapeptides | |||
| FK228 (romidepsin) | Class I | nM | Approved, I/II |
| Benzamides | |||
| MS275 (entinostat) | HDAC1, 2, 3 | µM | Phase II |
| MGCD0103 (mocetinostat) | Class I | µM | Phase II |
| Short-chain fatty acids | |||
| Valproic acid | Classes I and IIa | mM | Phase II |
| Butyrate | Classes I and IIa | mM | Phase II |